Clinical trials: Pulmonary Arterial Hypertension PAH
Pulmonary Arterial Hypertension
Safety, Tolerability, & Pharmacokinetics Study of Single & Multiple Inhaled Doses of Imatinib Inhalation Solution
This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib inhalation solution (AER-901) in healthy adult…
- Trial name
- NCT04903730
- Testing
- AER-901 Solution for Nebulization
- Where
- Australia
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Aerami Therapeutics
Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH)
Genetic Hallmarks of Patients With Congenital Portosystemic Shunts and Portopulmonary Hypertension
Congenital portosystemic shunt (CPSS) are rare vascular malformations causing blood from the intestines to bypass the liver and directly flow into body's general circulation.
- Conditions
- Portopulmonary Hypertension, Pulmonary Arterial Hypertension (PAH), Congenital Portosystemic Shunt
- Trial name
- Gen-PoPH-CPSS (NCT07314814)
- Testing
- targeted gene panels analysis, whole genome analysis
- Where
- Switzerland
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Prof. Valérie Mc Lin
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Pulmonary Arterial Hypertension
Study of ACT-293987 (NS-304) in Pulmonary Arterial Hypertension (PAH)
This is a multi-centre, multinational, open-label, single-dose acute hemodynamic study followed by randomized, double-blind, parallel-group, placebo controlled study.
- Trial name
- NCT00993408
- Testing
- ACT-293987 (NS-304)
- Where
- 8 sites in Austria, Belgium and 6 more
- Volunteers
- 43 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III.
- Trial name
- NCT05934526
- Testing
- Seralutinib, Generic Dry Powder Inhaler
- Where
- 166 sites in United States, Argentina and 29 more
- Volunteers
- 390 people
- Sponsor
- GB002, Inc.
Pulmonary Arterial Hypertension
A Pulmonary Arterial Hypertension Study With Macitentan to Validate the PAH-SYMPACT™ in France, Italy and Spain
Prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study. Primary objectives: To evaluate the psychometric characteristics of reliability and construct validity of the French, Italian and Spanish…
- Trial name
- ORCHESTRA (NCT02081690)
- Testing
- Macitentan
- Where
- 39 sites in France, Italy and 1 more
- Volunteers
- 160 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
IMPAHCT: Inhaled iMatinib Pulmonary Arterial Hypertension Clinical Trial is a Phase 2b/Phase 3 study to evaluate the safety and efficacy of AV-101 (dry powder inhaled imatinib) in patients with Pulmonary Arterial Hypertension…
- Trial name
- IMPAHCT (NCT05036135)
- Testing
- AV-101
- Where
- 128 sites in United States, Argentina and 24 more
- Volunteers
- 202 people
- Sponsor
- Aerovate Therapeutics
Pulmonary Arterial Hypertension
Study of the Initial Combination of Bosentan With Iloprost in the Treatment of Pulmonary Hypertension Patients
Previous studies suggest that combinations of existing therapies may be effective for pulmonary arterial hypertension (PAH). However, all of these studies are sequential combination therapy, for example, by adding sildenafil to…
- Trial name
- BIPH (NCT01712997)
- Testing
- Iloprost, Bosentan
- Where
- 2 sites in China
- Volunteers
- 90 people
- Sponsor
- Air Force Military Medical University, China
Pulmonary Arterial Hypertension
[18F]FES PET/CT in PAH
In this study positron emission tomography (PET/CT) imaging will be used to evaluate evaluation of estrogen receptor heterogeneity and functionality in Pulmonary Arterial Hypertension (PAH) using the investigational radiotracer…
- Trial name
- NCT02899533
- Testing
- [18F] FES
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Pennsylvania
Pulmonary Arterial Hypertension, Heart Defects, Congenital
The Effects of the Otago Exercise Program
The objective of this experimental study is to conduct a comparative evaluation of the effects of a supervised Otago Exercise Program (OEP) functional exercise capacity, blood lactate levels, dyspnea, fatigue, peripheral muscle…
- Trial name
- NCT06172790
- Testing
- Training
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- Istanbul University - Cerrahpasa
Idiopathic Pulmonary Arterial Hypertension
Virtual Reality in Patients With Pulmonary Hypertension: A Randomized Controlled Trial
The goal of this research is to investigate the effectiveness of exercise administered via immersive virtual reality in patients with pulmonary hypertension, thereby contributing to the existing literature on this subject.
- Trial name
- NCT07558460
- Testing
- Virtual Reality Group
- Where
- Turkey (Türkiye)
- Volunteers
- 32 people
- Sponsor
- Istanbul University - Cerrahpasa
Pulmonary Arterial Hypertension
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pressures in the blood vessels of the lungs that is not caused by another disease processes.
- Trial name
- TYEGER (NCT04280523)
- Testing
- ESR-specific PET scan
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Pulmonary Arterial Hypertension
An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)
The primary purpose of the study is to evaluate the safety and tolerability of the long-term use of TPIP in participants with PAH from studies INS1009-201 (NCT04791514), INS1009-202 (NCT05147805) and other lead-in studies of TPIP…
- Trial name
- NCT05649748
- Testing
- Treprostinil Palmitil
- Where
- 45 sites in United States, Argentina and 13 more
- Volunteers
- 91 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension
Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)
To evaluate the change from baseline in pulmonary vascular resistance (PVR), and other hemodynamic parameters, following the addition of ambrisentan to background phosphodiesterase type-5 inhibitor (PDE-5i) therapy in subjects…
- Trial name
- ATHENA-1 (NCT00617305)
- Testing
- Ambrisentan, Sildenafil, Tadalafil
- Where
- 30 sites in United States
- Volunteers
- 38 people
- Sponsor
- Gilead Sciences
Pulmonary Arterial Hypertension
A Dose Escalation Study to Evaluate the Effect of RT234 in Subjects With Pulmonary Arterial Hypertension
This multicenter, open label, Phase 2a study is designed to evaluate the effect of inhaled RT234 delivered in a dose escalation manner on the change in pulmonary vascular resistance (PVR) in subjects with Pulmonary Arterial…
- Trial name
- NCT05343637
- Testing
- Drug: RT234 - vardenafil inhalation powder; Device: RS01 dry powder inhaler (RS01 DPI)
- Where
- 3 sites in Australia
- Volunteers
- 14 people
- Sponsor
- Respira Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)
The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.
- Trial name
- NCT04712669
- Testing
- rodatristat ethyl 300 mg tablet BID, rodatristat ethyl 600 mg BID
- Where
- 64 sites in United States, Austria and 15 more
- Volunteers
- 108 people
- Sponsor
- Altavant Sciences GmbH
Pulmonary Arterial Hypertension
Safety and Efficacy of Continued CS1 Treatment of Patients With Pulmonary Arterial Hypertension
CS1-004 will be an extension of the CS1-003 Study. The primary objective of the CS1-004 study is to evaluate long-term safety and tolerability of continued treatment with CS1.
- Trial name
- NCT06321705
- Testing
- CS1
- Where
- Sweden
- Sponsor
- Cereno Scientific AB
Pulmonary Arterial Hypertension
Safety and Efficacy of Imatinib Mesylate in Patients With Pulmonary Arterial Hypertension
This study will evaluate the safety, tolerability, and efficacy of imatinib mesylate in patients with pulmonary arterial hypertension
- Trial name
- NCT00477269
- Testing
- Imatinib mesylate
- Where
- 13 sites in United States, Austria and 2 more
- Volunteers
- 59 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension, Pulmonary Arterial Hypertension
Rutgers University Study of the Genetics of Pulmonary Hypertension
The goal of this observational study is to learn more about how genes impact the risk of pulmonary hypertension. Anyone 18 or older living in the US is eligible, and a diagnosis of PH is NOT required.
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension Associated With Connective Tissue Disease
- Trial name
- RUGCC-PH (NCT07217522)
- Testing
- Saliva sample, Health surveys
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Pulmonary Arterial Hypertension
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments.
- Trial name
- REAPPRAISED (NCT07374302)
- Volunteers
- 15 people
- Sponsor
- Caio Júlio César dos Santos Fernandes